Last reviewed · How we verify
NCT04026191
OVT for Epicondylosis (Tennis Elbow)
NA trial testing OrthoVisc®-T (OVT) in Epicondylitis, Lateral in 50 participants. Completed in 31 December 2020.
31 December 2020
Quick facts
| Lead sponsor | Anika Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 19 July 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 3 locations across Czechia |
Drugs / interventions tested
- OrthoVisc®-T (OVT)
Conditions studied
- Epicondylitis, Lateral — all drugs for Epicondylitis, Lateral →
- Tendinopathy, Elbow — all drugs for Tendinopathy, Elbow →
Sponsor
Anika Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Epicondylitis, Lateral or Tendinopathy, Elbow. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the residual risk of OrthoVisc-T (OVT) for the treatment of chronic lateral epicondylosis (Tennis Elbow). This trial will provide clinical data on a subject population not previously researched which have failed prior treatments for lateral epicondylosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04026191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epicondylitis, Lateral
Currently open trials in the same condition.
- NCT07427368 — Comparison of ESWT and Ultrasound-Guided Ozone Injection in Lateral Epicondylitis · NA · recruiting
- NCT06587412 — Treatment of Lateral Epicondylalgia With Shock Waves · NA · recruiting
Other Anika Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT04640298 — Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint · NA · completed
- NCT04640961 — Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint · NA · completed
- NCT04640974 — Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle Joint · NA · completed
- NCT04231318 — Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain · Phase 3 · completed
- NCT04204265 — MONOVISC for Shoulder Joint Pain Relief Due to Osteoarthritis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04026191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anika Therapeutics, Inc.
- Last refreshed: 8 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04026191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing